11.22 USD
▼-0.17-1.49%
盘后 11.36 0.00%
2026-11-20
市值
$217.44M
市盈率
—
EPS
-2.86
股息率
—
52 周区间
8.98 – 22.55
成交量
126.93K
Beta
1.19
目标价
20.00
52W 低 8.9852W 高 22.55
价格走势
公司简介
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that...